Short answer
Axsome Therapeutics, Inc. (AXSM) filed an 8-K current report with the SEC on June 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). New executive severance plan effective June 5, 2026, covering named officers and other key employees.
Axsome Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- New executive severance plan effective June 5, 2026, covering named officers and other key employees
- Non-change-in-control severance: 18 months’ salary for CEO, 12 months for other Section 16 officers, 6 months for vice presidents
- Change-in-control severance: 24, 18, or 9 months’ salary plus target incentive payments by employee tier
- Change-in-control terminations accelerate 100% of time-based equity and target-level performance awards
- Plan supersedes prior severance arrangements, creating potentially significant acquisition-related cash and equity obligations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axsome Therapeutics, Inc. 8-K filings
Get the next AXSM 8-K as it lands
Follow AXSM for push alerts, or ask the research agent what this filing means.